Canaccord Adams initiates coverage on AspenBio Pharma (Nasdaq: APPY) with a Buy rating and $13 price target.

Analyst Matthew ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE